Upfront Autologous Stem Cell Transplantation for Untreated High-Risk Diffuse Large B-Cell Lymphoma in Patients Up to 60 Years of Age.

CONCLUSION: These results suggest that adding rituximab to upfront HDT/ASCT is feasible and can improve the outcome in untreated patients with poor-prognosis DLBCL. In the future, upfront HDT/ASCT should be more extensively evaluated in clinical trials.
PMID: 23763919 [PubMed - as supplied by publisher]

Source: Clinical Lymphoma and Myeloma - June 10, 2013 Category: Cancer & Oncology Authors: Takasaki H, Hashimoto C, Fujita A, Matsumoto K, Taguchi J, Kuwabara H, Yamazaki E, Koharazawa H, Fujita H, Fujisawa S, Ishii Y, Yamamoto W, Motomura S, Tomita N, Ishigatsubo Y, Sakai R Tags: Clin Lymphoma Myeloma Leuk Source Type: research